|
1
|
Chen Q, Su Y, He X, Zhao W, Wu C, Zhang W,
Si X, Dong B, Zhao L, Gao Y, et al: Plasma long non-coding RNA
MALAT1 is associated with distant metastasis in patients with
epithelial ovarian cancer. Oncol Lett. 12:1361–1366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Landen CN Jr, Birrer MJ and Sood AK: Early
events in the pathogenesis of epithelial ovarian cancer. J Clin
Oncol. 26:995–1005. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang HS, Feng YJ and Yao LQ: Angiogenesis,
vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int J
Gynecol Cancer. 19:605–610. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G,
Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, et al:
Surgical stress promotes tumor growth in ovarian carcinoma. Clin
Cancer Res. 15:2695–2702. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kroep JR and Nortier JW: The role of
bevacizumab in advanced epithelial ovarian cancer. Curr Pharm Des.
18:3775–3783. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato S and Itamochi H: Bevacizumab and
ovarian cancer. Curr Opin Obstet Gynecol. 24:8–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tejpar S, Prenen H and Mazzone M:
Overcoming resistance to antiangiogenic therapies. Oncologist.
17:1039–1050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hurst JH and Hooks SB: Regulator of
G-protein signaling (RGS) proteins in cancer biology. Biochem
Pharmacol. 78:1289–1297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lappano R and Maggiolini M: G
protein-coupled receptors: Novel targets for drug discovery in
cancer. Nat Rev Drug Discov. 10:47–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Perschbacher KJ, Deng G, Fisher RA,
Gibson-Corley KN, Santillan MK and Grobe JL: Regulators of
G-protein signaling in cardiovascular function during pregnancy.
Physiol Genomics. 50:590–604. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitchell TS, Bradley J, Robinson GS, Shima
DT and Ng YS: RGS5 expression is a quantitative measure of pericyte
coverage of blood vessels. Angiogenesis. 11:141–151. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aird WC: Endothelial cell heterogeneity.
Cold Spring Harb Perspect Med. 2:a0064292012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hida K, Hida Y, Amin DN, Flint AF,
Panigrahy D, Morton CC and Klagsbrun M: Tumor-associated
endothelial cells with cytogenetic abnormalities. Cancer Res.
64:8249–8255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
National Comprehensive Cancer Network
(NCCN): NCNN clinical practice guidelines in Oncology. Ovarian
cancer including fallopian tube cancer and primary peritoneal
cancer (V2.2018). https://www.nccn.org/patientsMarch 9–2018
|
|
15
|
Xu Y, Wang D, Zhao LM, Zhao XL, Shen JJ,
Xie Y, Cao LL, Chen ZB, Luo YM, Bao BH and Liang ZQ: Endoglin is
necessary for angiogenesis in human ovarian carcinoma-derived
primary endothelial cells. Cancer Biol Ther. 14:937–948. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho H, Kozasa T, Bondjers C, Betsholtz C
and Kehrl JH: Pericyte-specific expression of Rgs5: Implications
for PDGF and EDG receptor signaling during vascular maturation.
FASEB J. 17:440–442. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghosh K, Thodeti CK, Dudley AC, Mammoto A,
Klagsbrun M and Ingber DE: Tumor-derived endothelial cells exhibit
aberrant Rho-mediated mechanosensing and abnormal angiogenesis in
vitro. Proc Natl Acad Sci USA. 105:11305–11310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Z, Zuo Y, Wang J, Yu Z, Peng F, Chen Y,
Dong Y, Hu X, Zhou Q, Ma H, et al: Overexpression of the regulator
of G-protein signaling 5 reduces the survival rate and enhances the
radiation response of human lung cancer cells. Oncol Rep.
33:2899–2907. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng WL, Wang PX, Wang T, Zhang Y, Du C,
Li H and Ji Y: Regulator of G-protein signalling 5 protects against
atherosclerosis in apolipoprotein E-deficient mice. Br J Pharmacol.
172:5676–5689. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan L, Yang H, Xu C, Chen S, Meng Z, Li K
and Chen H: ZNF750 inhibited the malignant progression of oral
squamous cell carcinoma by regulating tumor vascular
microenvironment. Biomed Pharmacother. 105:566–572. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mills GB and Moolenaar WH: The emerging
role of lysophosphatidic acid in cancer. Nat Rev Cancer. 3:582–591.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abramow-Newerly M, Roy AA, Nunn C and
Chidiac P: RGS proteins have a signalling complex: Interactions
between RGS proteins and GPCRs, effectors, and auxiliary proteins.
Cell Signal. 18:579–591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tesmer JJ, Berman DM, Gilman AG and Sprang
SR: Structure of RGS4 bound to AlF4-activated G(i alpha1):
Stabilization of the transition state for GTP hydrolysis. Cell.
89:251–261. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang JH, Huang WS, Hu CR, Guan XX, Zhou HB
and Chen LB: Relationship between RGS5 expression and
differentiation and angiogenesis of gastric carcinoma. World J
Gastroenterol. 16:5642–5646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Silini A, Ghilardi C, Figini S, Sangalli
F, Fruscio R, Dahse R, Pedley RB, Giavazzi R and Bani M: Regulator
of G-protein signaling 5 (RGS5) protein: A novel marker of cancer
vasculature elicited and sustained by the tumor's proangiogenic
microenvironment. Cell Mol Life Sci. 69:1167–1178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nassiri F, Cusimano MD, Scheithauer BW,
Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K and Lloyd RV:
Endoglin (CD105): A review of its role in angiogenesis and tumor
diagnosis, progression and therapy. Anticancer Res. 31:2283–2290.
2011.PubMed/NCBI
|
|
27
|
Taskiran C, Erdem O, Onan A, Arisoy O,
Acar A, Vural C, Erdem M, Ataoglu O and Guner H: The prognostic
value of endoglin (CD105) expression in ovarian carcinoma. Int J
Gynecol Cancer. 16:1789–1793. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raspollini MR, Amunni G, Villanucci A,
Baroni G, Boddi V, Rossi Degl'innocenti D and Taddei GL:
Microvessel density in ovarian carcinoma: Computer image analysis
in patients with shorter and longer survival. Int J Gynecol Cancer.
15:844–849. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cantu De León D, Lopez-Graniel C, Frias
Mendivil M, Chanona Vilchis G, Gomez C and De La Garza Salazar J:
Significance of microvascular density (MVD) in cervical cancer
recurrence. Int J Gynecol Cancer. 13:856–862. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Uzzan B, Nicolas P, Cucherat M and Perret
GY: Microvessel density as a prognostic factor in women with breast
cancer: A systematic review of the literature and meta-analysis.
Cancer Res. 64:2941–2955. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang G, Song H, Wang R, Han X and Chen L:
The relationship between RGS5 expression and cancer differentiation
and metastasis in non-small cell lung cancer. J Surg Oncol.
105:420–424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ladds G, Goddard A, Hill C, Thornton S and
Davey J: Differential effects of RGS proteins on G alpha(q) and G
alpha(11) activity. Cell Signal. 19:103–113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kurrey NK, K A and Bapat SA: Snail and
Slug are major determinants of ovarian cancer invasiveness at the
transcription level. Gynecol Oncol. 97:155–165. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Friedl P and Wolf K: Tumour-cell invasion
and migration: Diversity and escape mechanisms. Nat Rev Cancer.
3:362–374. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jin Y, An X, Ye Z, Cully B, Wu J and Li J:
RG S5, a hypoxia-inducible apoptotic stimulator in endothelial
cells. J Biol Chem. 284:23436–23443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cimpean AM, Saptefrati L, Ceausu R and
Raica M: Characterization of endoglin and Ki-67 expression in
endothelial cells from benign and malignant lesions of the uterine
cervix. Pathol Int. 59:695–700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu H, Qiu H, Song Y, Liu Y, Wang H, Lu M,
Deng M, Gu Y, Yin J, Luo K, et al: Cip2a promotes cell cycle
progression in triple-negative breast cancer cells by regulating
the expression and nuclear export of p27Kip1. Oncogene.
36:1952–1964. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao S, Wang Y, Guo T, Yu W, Li J, Tang Z,
Yu Z, Zhao L, Zhang Y, Wang Z, et al: YBX1 regulates tumor growth
via CDC25a pathway in human lung adenocarcinoma. Oncotarget.
7:82139–82157. 2016.PubMed/NCBI
|
|
39
|
Nilsson I and Hoffmann I: Cell cycle
regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res.
4:107–114. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Anger T, El-Chafchak J, Habib A, Stumpf C,
Weyand M, Daniel WG, Hombach V, Hoeher M and Garlichs CD: Statins
stimulate RGS-regulated ERK 1/2 activation in human calcified and
stenotic aortic valves. Exp Mol Pathol. 85:101–111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
